Although secondary mutations and compensatory bypass pathways have been demonstrated to lead resistance to Osimertinib in EGFR mutant NSCLC, there is still a big gap of knowledge regarding resistance machineries. Here, EGFR is linked to non-small cell lung carcinoma.